Literature DB >> 18825791

The impact of intensive insulin protocols and restrictive blood transfusion strategies on glucose measurement in American Burn Association (ABA) verified burn centers.

Elizabeth A Mann1, Heather F Pidcoke, Jose Salinas, John B Holcomb, Steven E Wolf, Charles E Wade.   

Abstract

The prevalence of intensive insulin and restrictive blood use protocols in burn centers is unknown, which may be problematic as the combined impact of these therapies is to concomitantly increase the prevalence of anemia and hypoglycemia in intensive care unit patients. Such a development is important because point-of-care (POC) glucometers report erroneously high values in the presence of low hematocrit (HCT), potentially masking the presence of hypoglycemia. We hypothesized that most American Burn Association (ABA) verified burn centers have adopted intensive insulin therapy while simultaneously restricting blood transfusions potentially increasing risk of hypoglycemia. All ABA verified burn centers (N = 44) were contacted. Clinical practices regarding intensive insulin therapy, restrictive transfusion practices, and the use of POC glucometers were evaluated. Intensive insulin protocols were implemented at 73% of ABA centers (defined as upper glucose target of < or = 120 mg/dl) and POC glucometers measurement was nearly universal; 95% of ABA centers use them routinely. Anemia is prevalent in intensive care units and may be increasing because of recent changes in practice. Defined hemoglobin and HCT levels trigger blood transfusion at 84% of centers, and of these, 51% restrict transfusion to hemoglobin < 7 g/dl or HCT < 22%. Most ABA centers now use intensive insulin protocols, many in combination with restrictive transfusion strategies. The combination of a higher prevalence of hypoglycemia in the presence of near universal anemia is concerning, particularly given the pervasiveness of glucometer use among burn centers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18825791     DOI: 10.1097/BCR.0b013e3181848c74

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  8 in total

Review 1.  Glycemic control in the burn intensive care unit: focus on the role of anemia in glucose measurement.

Authors:  Elizabeth A Mann; Alejandra G Mora; Heather F Pidcoke; Steven E Wolf; Charles E Wade
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

2.  Diabetes does not influence selected clinical outcomes in critically ill burn patients.

Authors:  Chaitanya K Dahagam; Alejandra Mora; Steven E Wolf; Charles E Wade
Journal:  J Burn Care Res       Date:  2011 Mar-Apr       Impact factor: 1.845

3.  Plasma-generating glucose monitor accuracy demonstrated in an animal model.

Authors:  Peggy Magarian; Bernhard Sterling
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

4.  Computer decision support software safely improves glycemic control in the burn intensive care unit: a randomized controlled clinical study.

Authors:  Elizabeth A Mann; John A Jones; Steven E Wolf; Charles E Wade
Journal:  J Burn Care Res       Date:  2011 Mar-Apr       Impact factor: 1.845

5.  Automated near-continuous glucose monitoring measured in plasma using mid-infrared spectroscopy.

Authors:  Thomas Jax; Tim Heise; Leszek Nosek; Jennifer Gable; Gene Lim; Christopher Calentine
Journal:  J Diabetes Sci Technol       Date:  2011-03-01

6.  Anemia causes hypoglycemia in intensive care unit patients due to error in single-channel glucometers: methods of reducing patient risk.

Authors:  Heather F Pidcoke; Charles E Wade; Elizabeth A Mann; Jose Salinas; Brian M Cohee; John B Holcomb; Steven E Wolf
Journal:  Crit Care Med       Date:  2010-02       Impact factor: 7.598

Review 7.  The role of hyperglycemia in burned patients: evidence-based studies.

Authors:  Gabriel A Mecott; Ahmed M Al-Mousawi; Gerd G Gauglitz; David N Herndon; Marc G Jeschke
Journal:  Shock       Date:  2010-01       Impact factor: 3.454

Review 8.  Clinical review: Glucose control in severely burned patients - current best practice.

Authors:  Marc G Jeschke
Journal:  Crit Care       Date:  2013-07-25       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.